Skip to main
CING
CING logo

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate Inc operates within a growing market, with total ADHD medication sales in the U.S. experiencing an approximate annual growth rate of 8% since 2010, culminating in a market size of around $18 billion by 2020. In July 2023, the company released positive topline results from its CTx-1301 trial, indicating a favorable response among subjects compared to those receiving a placebo. The combination of a robust and expanding market alongside promising clinical trial outcomes suggests a significant upside potential for Cingulate's stock, indicating a positive outlook despite the inherent risks associated with biopharmaceutical development.

Bears say

Cingulate Inc reported a net loss of $4.8 million, translating to an earnings per share (EPS) of $(1.09), which fell short of internal estimates of $(0.90) and consensus expectations of $(0.87). The company faces several significant risks that could affect its financial health and stock performance, including balance sheet and liquidity issues, the potential failure of product candidates in clinical trials, and challenges in securing regulatory approvals. Additionally, competition and macroeconomic factors, along with changing investor sentiment towards biotech investments, further contribute to a challenging outlook for Cingulate's stock.

Cingulate (CING) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.